Morgan Stanley has lowered its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) to $5 from $8, while maintaining an Equal Weight rating on the stock.

Recursion, Exscientia, and AI drug discovery’s moment of truth Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger.

Read about Recursion Pharmaceuticals Inc Class A (RXRX:XNAS) stock and today's latest news and financial updates.

Review which funds and institutions currently hold Recursion Pharmaceuticals Inc Class A (RXRX:XNAS) stock for ownership information.

Discover the latest Architecture news and projects on Architectural Visualization at ArchDaily, the world's largest architecture website. Stay up-to-date with articles and updates on the newest ...

Stay up-to-date on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq.com.